COVID-19 and the Pediatric Heart

Detalhes bibliográficos
Autor(a) principal: Henriques, Cláudio
Data de Publicação: 2022
Outros Autores: Álvares, Sílvia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25753/BirthGrowthMJ.v31.i3.27950
Resumo: Coronavirus disease stormed into our lives in 2019 with first reports of infection occurring in Wuhan, China. It spares no one, despite having a traditionally milder course in children. Still, a novel hyperinflammatory post COVID-19 entity has emerged between the pediatric age group implicating higher severeness and cardiac disease. Multisystem inflammatory syndrome in children (MIS-C) shares several key characteristics with other hyperinflammation associated diseases and treatment options usually overlap between them. Immunomodulatory therapy has shown to reduce the risk of complications and severe disease. Vaccination can rarely be associated with severe side effects, but risk-benefit assessment has a favourable balance towards vaccination. Despite the scarcity of data, pediatric long COVID-19 symptoms have been systematically described with a significant impact on children’s lives in the long run.
id RCAP_5dc479c34cc2b89ec32a8e4f39dc6c3d
oai_identifier_str oai:ojs.revistas.rcaap.pt:article/27950
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling COVID-19 and the Pediatric HeartCOVID-19 e o Coração PediátricoReview ArticlesCoronavirus disease stormed into our lives in 2019 with first reports of infection occurring in Wuhan, China. It spares no one, despite having a traditionally milder course in children. Still, a novel hyperinflammatory post COVID-19 entity has emerged between the pediatric age group implicating higher severeness and cardiac disease. Multisystem inflammatory syndrome in children (MIS-C) shares several key characteristics with other hyperinflammation associated diseases and treatment options usually overlap between them. Immunomodulatory therapy has shown to reduce the risk of complications and severe disease. Vaccination can rarely be associated with severe side effects, but risk-benefit assessment has a favourable balance towards vaccination. Despite the scarcity of data, pediatric long COVID-19 symptoms have been systematically described with a significant impact on children’s lives in the long run.A doença por coronavírus entrou de rompante nas nossas vidas em 2019 com os primeiros casos reportados oriundos da cidade de Wuhan na China. A sua prevalência afetou-nos a todos, apesar das crianças apresentarem tendencialmente doença ligeira. Porém, uma nova forma de apresentação da doença, que consiste em síndrome hiperinflamatório pós COVID-19, tem emergido no grupo pediátrico, implicando maior severidade e envolvimento cardíaco. A síndrome inflamatória multissistémica em crianças (MIS-C) apresenta semelhanças importantes com outros síndromes hiperinflamatórios conhecidos, partilhando, desta forma, as suas opções terapêuticas. A terapêutica imunomodeladora tem provado reduzir o risco de complicações e severidade da doença. A vacinação pode, raramente, ter efeitos secundários graves, mas o risco-benefício abona sempre em favor da sua utilização. Apesar da escassez de dados, os sintomas a longo prazo no grupo pediátrico após infeção por COVID-19 (Covid Longa) têm sido sistematicamente descritos com impacto significativo a longo prazo na vida das crianças.Centro Hospitalar Universitário do Porto2022-10-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://doi.org/10.25753/BirthGrowthMJ.v31.i3.27950eng2183-9417Henriques, CláudioÁlvares, Sílviainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-10-20T17:00:19Zoai:ojs.revistas.rcaap.pt:article/27950Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:13:21.514870Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv COVID-19 and the Pediatric Heart
COVID-19 e o Coração Pediátrico
title COVID-19 and the Pediatric Heart
spellingShingle COVID-19 and the Pediatric Heart
Henriques, Cláudio
Review Articles
title_short COVID-19 and the Pediatric Heart
title_full COVID-19 and the Pediatric Heart
title_fullStr COVID-19 and the Pediatric Heart
title_full_unstemmed COVID-19 and the Pediatric Heart
title_sort COVID-19 and the Pediatric Heart
author Henriques, Cláudio
author_facet Henriques, Cláudio
Álvares, Sílvia
author_role author
author2 Álvares, Sílvia
author2_role author
dc.contributor.author.fl_str_mv Henriques, Cláudio
Álvares, Sílvia
dc.subject.por.fl_str_mv Review Articles
topic Review Articles
description Coronavirus disease stormed into our lives in 2019 with first reports of infection occurring in Wuhan, China. It spares no one, despite having a traditionally milder course in children. Still, a novel hyperinflammatory post COVID-19 entity has emerged between the pediatric age group implicating higher severeness and cardiac disease. Multisystem inflammatory syndrome in children (MIS-C) shares several key characteristics with other hyperinflammation associated diseases and treatment options usually overlap between them. Immunomodulatory therapy has shown to reduce the risk of complications and severe disease. Vaccination can rarely be associated with severe side effects, but risk-benefit assessment has a favourable balance towards vaccination. Despite the scarcity of data, pediatric long COVID-19 symptoms have been systematically described with a significant impact on children’s lives in the long run.
publishDate 2022
dc.date.none.fl_str_mv 2022-10-19
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25753/BirthGrowthMJ.v31.i3.27950
url https://doi.org/10.25753/BirthGrowthMJ.v31.i3.27950
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2183-9417
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Centro Hospitalar Universitário do Porto
publisher.none.fl_str_mv Centro Hospitalar Universitário do Porto
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130587583217664

Registros relacionados